Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Open access
Dreger, Peter, Schetelig, Johannes, Andersen, Niels, Corradini, Paolo, van Gelder, Michel, Gribben, John, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Stilgenbauer, Stephan, Montserrat, Emili·2014·Blood

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel classes of drugs. Among them, BCR signal inhibitors (BCRi) and B-cell lymphoma 2 antagonists (BCL2a) appear particularly promising. As a result of the growing body of favorable outcome data reported for BCRi/BCL2a, uncertainty is emerging on how to advise patients with HR-CLL about indication for and timing of HSCT. This article provides an overview of currently available evidence and theoretical considerations to guide this difficult decision process. Until the risks and benefits of different treatment strategies are settled, all patients with HR-CLL should be considered for treatment with BCRi/BCL2a. For patients who respond to these agents, there are 2 treatment possibilities: (1) performing an HSCT or (2) continuing treatment with the novel drug. Individual disease-specific and transplant-related risk factors, along with patient’s preferences, should be taken into account when recommending one of these treatments over the other.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2014-07-586826

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 199

Metadata

Authors
Dreger, P., Schetelig, J., Andersen, N., Corradini, P., van Gelder, M., Gribben, J., Kimby, E., Michallet, M., Moreno, C., Stilgenbauer, S., & Montserrat, E.
Venue
Blood
Published
2014-12-18
Volume
124
Issue
26
Pages
3841-3849
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1970312642
Cited by
199
References
7
FWCI
15.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? https://app.cochat.ai/papers/10.1182/blood-2014-07-586826
The paper
Dreger, P., Schetelig, J., Andersen, N., Corradini, P., van Gelder, M., Gribben, J., Kimby, E., Michallet, M., Moreno, C., Stilgenbauer, S., & Montserrat, E. (2014). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. https://doi.org/10.1182/blood-2014-07-586826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.